Skip to main content
Fig. 2 | Cell & Bioscience

Fig. 2

From: Selonsertib, a potential drug for liver failure therapy by rescuing the mitochondrial dysfunction of macrophage via ASK1–JNK–DRP1 pathway

Fig. 2

The therapeutic efficacy of selonsertib is related to JNK mitochondrial translocation. a, b Western blot analysis and grey value assay of p-JNK and JNK levels in murine whole liver samples (a) and the mitochondrial fraction of liver samples (b); 1 or 2 from 6 samples are shown in the blots. c Serum levels of ALT, AST, and TBIL in different groups with selonsertib pretreatment (Pre) or treatment at 0.5 h, 1 h, 2 h, and 4 h after LPS/GalN injection. d Pathological changes in the liver tissue were shown by H&E staining. e The serum levels of inflammatory cytokines and chemokines were determined by CBA cytokine analysis. f, g Western blot analysis of p-JNK and JNK levels in murine whole liver samples (f) and the mitochondrial fraction of liver samples (g) at initial (0 h) and 0.5 h, 1 h, 2 h, and 4 h after LPS/GalN injection (2 from 6 samples are shown in the blots). Data are presented as the mean ± SD (n = 6). *P < 0.05 vs. vehicle; **P < 0.01 vs. vehicle; ***P < 0.001 vs. vehicle; ##P < 0.01 vs. vehicle; ###P < 0.001 vs. vehicle; ns not significant vs. vehicle, NC normal control, SEL selonsertib (30 mg/kg)

Back to article page

Cell & Bioscience

ISSN: 2045-3701

Contact us